Sotatercept-csrk reduced the risk of major morbidity and mortality events in adults with WHO Group 1 PAH FC 3 or 4 at high risk of mortality.

Patients were grouped into one of three subjective functional outcome groups, and those who had a surgical repair had a better functional outcome. Conclusions—Surgical repair results in greater ...